Skip to content
HowShorted

Puma Biotechnology Inc short interest in 2018

In 2018, Puma Biotechnology Inc's disclosed short interest ran from 7.31% of shares outstanding on 12 Jan 2018 to 10.89% on 31 Dec 2018, a change of +3.58 percentage points. The year's high was 13.33% on 15 Oct 2018 and its low 7.19% on 31 May 2018, averaging 9.92% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.79 days on 13 Jul 2018. Full history: Puma Biotechnology Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Puma Biotechnology Inc in 2018

2018 in figures

Start of year
7.31% (12 Jan 2018)
End of year
10.89% (31 Dec 2018)
Change
+3.58 pp
High
13.33% (15 Oct 2018)
Low
7.19% (31 May 2018)
Average
9.92%
Highest days to cover
7.79 (13 Jul 2018)
SEC filings marked
8

Every report in 2018

Puma Biotechnology Inc short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20187.31%4.58
31 Jan 20189.13%1.97
15 Feb 20189.63%3.78
28 Feb 20189.26%5.38
15 Mar 20188.62%2.65results (8-K), 10-K filed
29 Mar 20188.71%5.35
13 Apr 20188.30%4.68
30 Apr 20188.26%6.38
15 May 20187.92%2.59results (8-K), 10-Q filed
31 May 20187.19%4.78
15 Jun 20187.29%3.05
29 Jun 201812.01%2.70
13 Jul 201812.71%7.79
31 Jul 201812.16%7.72
15 Aug 201811.41%3.5710-Q filed, results (8-K)
31 Aug 20189.56%5.69
14 Sep 201810.59%4.50
28 Sep 201812.16%6.98
15 Oct 201813.33%7.60
31 Oct 201812.34%6.14
15 Nov 20189.96%1.01results (8-K), 10-Q filed
30 Nov 201810.16%4.96
14 Dec 20189.28%3.55
31 Dec 201810.89%3.12

See also: Puma Biotechnology Inc's full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.